Insider transactions

EDGAR

Quest Diagnostics Incorporated

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
41 transactions, 217,384 shares
Sum of shares × price per share: 47,360,613.9362

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 167

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-13 Filed 2026-11-16Deppe Michael J Officer: SVP, Corp. Controller CAO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6,26195.795
599,772.495

Derived: shares × price per share. Exact value 599772.495.

41,464Direct (D) Yes
F1
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000127 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Deppe Michael J Officer: SVP, Corp. Controller CAO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,261260.17
1,628,924.37

Derived: shares × price per share. Exact value 1628924.37.

35,203Direct (D) Yes
F1
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000127 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Deppe Michael J Officer: SVP, Corp. Controller CAO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,515103.57
571,188.55

Derived: shares × price per share. Exact value 571188.55.

40,718Direct (D) Yes
F1
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000127 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Deppe Michael J Officer: SVP, Corp. Controller CAO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,515260.17
1,434,837.55

Derived: shares × price per share. Exact value 1434837.55.

35,203Direct (D) Yes
F1, F2
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F2 The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
Open filing 0001022079-26-000127 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Deppe Michael J Officer: SVP, Corp. Controller CAO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-Qualifed Stock Option (right to buy) — underlying Common Stock (6,261) — exercise price 95.795
Disposed (D)6,26195.795
599,772.495

Derived: shares × price per share. Exact value 599772.495.

0Direct (D) Yes
F1, F4
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F4 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.
Open filing 0001022079-26-000127 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-16Deppe Michael J Officer: SVP, Corp. Controller CAO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-Qualifed Stock Option (right to buy) — underlying Common Stock (5,515) — exercise price 103.57
Disposed (D)5,515103.57
571,188.55

Derived: shares × price per share. Exact value 571188.55.

0Direct (D) Yes
F1, F4
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F4 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.
Open filing 0001022079-26-000127 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Plewman Patrick Officer: SVP for Diagnostic Services
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)4,274127.725
545,896.65

Derived: shares × price per share. Exact value 545896.650.

19,608Direct (D) Yes
F1
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000125 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Plewman Patrick Officer: SVP for Diagnostic Services
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,274257.34
1,099,871.16

Derived: shares × price per share. Exact value 1099871.16.

15,334Direct (D) Yes
F1
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000125 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Plewman Patrick Officer: SVP for Diagnostic Services
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6,793127.805
868,179.365

Derived: shares × price per share. Exact value 868179.365.

22,127Direct (D) Yes
F1
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000125 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Plewman Patrick Officer: SVP for Diagnostic Services
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,793257.34
1,748,110.62

Derived: shares × price per share. Exact value 1748110.62.

15,334Direct (D) Yes
F1
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000125 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Plewman Patrick Officer: SVP for Diagnostic Services
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)650257.34
167,271

Derived: shares × price per share. Exact value 167271.00.

14,684Direct (D) Yes
F2
  • F2 The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000125 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Plewman Patrick Officer: SVP for Diagnostic Services
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-Qualifed Stock Option (right to buy) — underlying Common Stock (4,274) — exercise price 127.725
Disposed (D)4,274127.725
545,896.65

Derived: shares × price per share. Exact value 545896.650.

0Direct (D) Yes
F1, F3
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F3 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.
Open filing 0001022079-26-000125 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Plewman Patrick Officer: SVP for Diagnostic Services
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-Qualifed Stock Option (right to buy) — underlying Common Stock (6,793) — exercise price 127.805
Disposed (D)6,793127.805
868,179.365

Derived: shares × price per share. Exact value 868179.365.

3,397Direct (D) Yes
F1, F3
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F3 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.
Open filing 0001022079-26-000125 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05DELANEY MARK E Officer: SVP Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,6150—12,975Direct (D) No
F1
  • F1 Represents an award of restricted stock units.
Open filing 0001022079-26-000121 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)4,8270—71,949Direct (D) Yes
F1
  • F1 Represents an award of restricted stock units.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)22,105121.805
2,692,499.525

Derived: shares × price per share. Exact value 2692499.525.

94,054Direct (D) Yes
F2
  • F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,818245.4519
937,135.3542

Derived: shares × price per share. Exact value 937135.3542.

90,236Direct (D) Yes
F2, F3
  • F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,990246.2649
1,475,126.751

Derived: shares × price per share. Exact value 1475126.7510.

84,246Direct (D) Yes
F2, F4
  • F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,151246.9835
284,278.0085

Derived: shares × price per share. Exact value 284278.0085.

83,095Direct (D) Yes
F2, F5
  • F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,358248.3838
585,689.0004

Derived: shares × price per share. Exact value 585689.0004.

80,737Direct (D) Yes
F2, F6
  • F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,004249.4035
749,208.114

Derived: shares × price per share. Exact value 749208.1140.

77,733Direct (D) Yes
F2, F7
  • F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,877250.4882
720,654.5514

Derived: shares × price per share. Exact value 720654.5514.

74,856Direct (D) Yes
F2, F8
  • F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,907251.2386
730,350.6102

Derived: shares × price per share. Exact value 730350.6102.

71,949Direct (D) Yes
F2, F9
  • F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Doherty Catherine T. Officer: Executive Vice President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-Qualifed Stock Option (right to buy) — underlying Common Stock (22,105) — exercise price 121.805
Disposed (D)22,105121.805
2,692,499.525

Derived: shares × price per share. Exact value 2692499.525.

0Direct (D) Yes
F2, F11
  • F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024.
Open filing 0001022079-26-000122 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Ramachandran Subu Officer: SVP, Regional Businesses
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3520—2,832Direct (D) No
F1
  • F1 Represents an award of restricted share units.
Open filing 0001022079-26-000123 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-05Ramachandran Subu Officer: SVP, Regional Businesses
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-Qualifed Stock Option (right to buy) — underlying Common Stock (1,386) — exercise price 248.61
Acquired (A)1,3860—1,386Direct (D) No
F2
  • F2 The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.
Open filing 0001022079-26-000123 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28PFEIFFER GARY M Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,203243
292,329

Derived: shares × price per share. Exact value 292329.

29,802Direct (D) Yes
F1
  • F1 This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000118 Read from the filing’s XML Dispute this row
2026-10-21 Filed 2026-10-23Plewman Patrick Officer: SVP for Diagnostic Services
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)41235.94
9,673.54

Derived: shares × price per share. Exact value 9673.54.

15,334Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000111 Read from the filing’s XML Dispute this row
2026-10-21 Filed 2026-10-23Gregg Vicky B Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)63235.939
14,864.157

Derived: shares × price per share. Exact value 14864.157.

18,449Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000114 Read from the filing’s XML Dispute this row
2026-10-21 Filed 2026-10-23SAMAD SAM Officer: Executive Vice President CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)90235.939
21,234.51

Derived: shares × price per share. Exact value 21234.510.

33,568Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000115 Read from the filing’s XML Dispute this row
2026-10-21 Filed 2026-10-23CARTER ROBERT B Director
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)10235.93
2,359.3

Derived: shares × price per share. Exact value 2359.30.

3,874Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000116 Read from the filing’s XML Dispute this row
2026-10-21 Filed 2026-10-23KUPPUSAMY KARTHIK Officer: SVP, Clinical Solutions
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)33235.944
7,786.152

Derived: shares × price per share. Exact value 7786.152.

13,619Direct (D) No
F1, F2
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
  • F2 The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
Open filing 0001022079-26-000113 Read from the filing’s XML Dispute this row
2026-10-21 Filed 2026-10-23Lassiter Wright III Director
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)6235.959
1,415.754

Derived: shares × price per share. Exact value 1415.754.

10,329Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000112 Read from the filing’s XML Dispute this row
2026-10-21 Filed 2026-10-23DELANEY MARK E Officer: SVP Chief Commercial Officer
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)25235.941
5,898.525

Derived: shares × price per share. Exact value 5898.525.

10,360Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000109 Read from the filing’s XML Dispute this row
2026-10-21 Filed 2026-10-23MAIN TIMOTHY L Director
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)18235.937
4,246.866

Derived: shares × price per share. Exact value 4246.866.

22,478Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000110 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02WENTWORTH TIMOTHY C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (135) — exercise price 0
Acquired (A)1350—477Direct (D) No
F1
  • F1 Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director.
Open filing 0001022079-26-000090 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-03Davis J. E. Director · Officer: CEO and President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)10,000242.72
2,427,200

Derived: shares × price per share. Exact value 2427200.00.

122,423Direct (D) Yes
F1
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001599837-26-000007 Read from the filing’s XML Dispute this row
2026-08-28 Filed 2026-08-31PREVOZNIK MICHAEL E Officer: SVP General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)22,677112.17
2,543,679.09

Derived: shares × price per share. Exact value 2543679.09.

60,234Direct (D) Yes
F1
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000089 Read from the filing’s XML Dispute this row
2026-08-28 Filed 2026-08-31PREVOZNIK MICHAEL E Officer: SVP General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)16,010242.8755
3,888,436.755

Derived: shares × price per share. Exact value 3888436.7550.

44,224Direct (D) Yes
F1, F2
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F2 This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000089 Read from the filing’s XML Dispute this row
2026-08-28 Filed 2026-08-31PREVOZNIK MICHAEL E Officer: SVP General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,237243.6275
1,519,504.7175

Derived: shares × price per share. Exact value 1519504.7175.

37,987Direct (D) Yes
F1, F3
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F3 This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000089 Read from the filing’s XML Dispute this row
2026-08-28 Filed 2026-08-31PREVOZNIK MICHAEL E Officer: SVP General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)430244.5148
105,141.364

Derived: shares × price per share. Exact value 105141.3640.

37,557Direct (D) Yes
F1, F4
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F4 This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Open filing 0001022079-26-000089 Read from the filing’s XML Dispute this row
2026-08-28 Filed 2026-08-31PREVOZNIK MICHAEL E Officer: SVP General Counsel
G

Bona fide gift

Common Stock
Disposed (D)1,0000—36,557Direct (D) Yes
F5
  • F5 On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000089 Read from the filing’s XML Dispute this row
2026-08-28 Filed 2026-08-31PREVOZNIK MICHAEL E Officer: SVP General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-Qualifed Stock Option (right to buy) — underlying Common Stock (22,677) — exercise price 112.17
Disposed (D)22,677112.17
2,543,679.09

Derived: shares × price per share. Exact value 2543679.09.

0Direct (D) Yes
F1, F7
  • F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  • F7 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.
Open filing 0001022079-26-000089 Read from the filing’s XML Dispute this row
2026-07-28 Filed 2026-07-29DELANEY MARK E Officer: SVP Chief Commercial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,600235.18
376,288

Derived: shares × price per share. Exact value 376288.00.

10,335Direct (D) Yes
F1
  • F1 This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
Open filing 0001022079-26-000087 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-27MAIN TIMOTHY L Director
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)21206.81
4,343.01

Derived: shares × price per share. Exact value 4343.01.

22,460Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000082 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-27Lassiter Wright III Director
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)6206.813
1,240.878

Derived: shares × price per share. Exact value 1240.878.

10,323Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000080 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-27SAMAD SAM Officer: Executive Vice President CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)102206.807
21,094.314

Derived: shares × price per share. Exact value 21094.314.

33,478Direct (D) No
F1, F2
  • F1 Represents an award of restricted share units.
  • F2 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000081 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-27Gregg Vicky B Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)72206.808
14,890.176

Derived: shares × price per share. Exact value 14890.176.

18,386Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000084 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-27CARTER ROBERT B Director
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)11206.804
2,274.844

Derived: shares × price per share. Exact value 2274.844.

3,864Direct (D) No
F1
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Open filing 0001022079-26-000085 Read from the filing’s XML Dispute this row
2026-07-22 Filed 2026-07-27KUPPUSAMY KARTHIK Officer: SVP, Clinical Solutions
L

Small acquisition under Rule 16a-6

Common Stock
Acquired (A)37206.807
7,651.859

Derived: shares × price per share. Exact value 7651.859.

13,557Direct (D) No
F1, F2
  • F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
  • F2 The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
Open filing 0001022079-26-000086 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–31 of 31

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Carol Devine Miller (WV01)2025-03-10Sale$15,001 - $50,0002026-08-13
Hon. Julie Johnson (TX32)2025-10-30Sale$1,001 - $15,000JT2026-08-05
Hon. Julie Johnson (TX32)2025-10-30Purchase$1,001 - $15,000JT2026-08-05
Hon. Julia Letlow (LA05)2025-04-28Purchase$1,001 - $15,0002026-01-13
Hon. Julia Letlow (LA05)2025-07-24Sale$1,001 - $15,0002026-01-13
Hon. Julie Johnson (TX32)2025-11-03Sale$1,001 - $15,000JT2025-12-11
Hon. Gilbert Cisneros (CA31)2025-01-24Sale (partial)$1,001 - $15,0002025-02-11
Hon. Earl Blumenauer (OR03)2024-04-04Sale$1,001 - $15,000SP2024-05-04
Hon. Carol Devine Miller (WV03)2022-11-14Purchase$1,001 - $15,0002022-12-13
Hon. Kathy Manning (NC06)2022-08-03Sale$1,001 - $15,000JT2022-09-14
Hon. Carol Devine Miller (WV03)2021-07-28Purchase$15,001 - $50,000SP2022-09-02
Hon. Kathy Manning (NC06)2022-07-20Purchase$1,001 - $15,000JT2022-08-10
Hon. Earl Blumenauer (OR03)2022-02-24Purchase$1,001 - $15,0002022-04-01
Hon. Earl Blumenauer (OR03)2022-03-14Sale$1,001 - $15,0002022-04-01
Hon. Sara Jacobs (CA53)2021-04-09Sale$50,001 - $100,0002021-05-28
Hon. Dean Phillips (MN03)2020-06-01Sale (partial)$1,001 - $15,0002020-07-07
Hon. Dean Phillips (MN03)2020-04-02Sale (partial)$1,001 - $15,0002020-05-07
Hon. Earl Blumenauer (OR03)2020-03-02Purchase$1,001 - $15,0002020-04-16
Hon. Dean Phillips (MN03)2020-02-10Sale (partial)$1,001 - $15,0002020-03-12
Hon. Dean Phillips (MN03)2020-01-17Purchase$1,001 - $15,0002020-02-07
Hon. Dean Phillips (MN03)2019-07-31Purchase$1,001 - $15,0002019-08-21
Hon. Dean Phillips (MN03)2019-05-03Purchase$1,001 - $15,0002019-06-13
Hon. Dean Phillips (MN03)2019-04-04Sale (partial)$1,001 - $15,0002019-05-21
Hon. Gilbert Cisneros (CA39)2019-03-14Purchase$1,001 - $15,0002019-04-16
Hon. Dean Phillips (MN03)2019-02-04Purchase$1,001 - $15,0002019-03-21
Hon. K. Michael Conaway (TX11)2016-09-12Sale$1,001 - $15,000SP2016-10-12
Hon. Lois Frankel (FL22)2016-06-20Sale$1,001 - $15,0002016-08-16
Hon. Lois Frankel (FL22)2015-05-27Sale$1,001 - $15,0002015-06-19
Mr. Richard L. Hanna (NY22)2014-10-15Sale$1,001 - $15,000JT2014-11-11
Mr. Richard L. Hanna (NY22)2013-12-27Sale$100,001 - $250,0002014-01-15
Mr. Richard L. Hanna (NY22)2013-12-30Sale$1,001 - $15,0002014-01-15

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
STATE STREET CORPORATION COMMON STOCK55,563,421.0009/30/2026 Filed 2026-11-10SCHEDULE 13GOpen filing 0000093751-26-000709 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK4.95,428,24406/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000080255-26-000528 Dispute this row
Vanguard Capital Management Common Stock7.538,274,56703/31/2026 Filed 2026-04-30SCHEDULE 13GOpen filing 0002100119-26-001044 Dispute this row
Vanguard Portfolio Management Common Stock5.546,096,62903/31/2026 Filed 2026-04-29SCHEDULE 13GOpen filing 0002100121-26-000570 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-27SCHEDULE 13G/AAmendment 13Open filing 0000102909-26-002167 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK6.57,209,62206/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0000080255-25-000562 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,700,931 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015117,313
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to Quest Diagnostics Incorporated